Breast cancer detection on mammography.
FDA cleared.
Vendor press release citing ‘330+ sites and 1M annual screenings’, covering over 14% of the Italian population via the public health system.
Not found in this research pass — the deployment figure above is vendor-reported; verify before publishing.
‘330+ sites and 1M annual screenings’ claimed by the vendor, notably including deployment within a PUBLIC national health system (Italy), not only private clinics.
Deployment scale is vendor-reported; seek independent confirmation (e.g. from the Italian health authority) before publishing as fact.
This profile is not medical advice or an endorsement. Hospitals should perform their own due diligence (regulatory compliance, GDPR, cybersecurity, integration, local clinical validation). How we evaluate
Every profile documents the precise indication, regulatory status, vendor-supported and independent evidence, real-world deployment, limits and dated sources.
A independent systematic review or prospective multicentre study · B at least one independent peer-reviewed study · C peer-reviewed, vendor-supported · D vendor claims only.
Vendors, authors and clinicians can request a correction. Corrections are dated on the profile.